Evidence map›Paper›PMID 34506305›Full record

ArticleThe Journal of clinical investigation2021

Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex.

Nida Haider, Jasmin Lebastchi, Ashok Kumar Jayavelu, Thiago M Batista, Hui Pan, Jonathan M Dreyfuss, Ivan Carcamo-Orive, Joshua W Knowles, Matthias Mann, C Ronald Kahn

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. The insulin signalling network.Nature metabolism · 2025
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nida HaiderSection of Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
Jasmin LebastchiSection of Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
Ashok Kumar JayaveluDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
Thiago M BatistaSection of Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
Hui PanBioinformatics and Biostatistics Core, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
Jonathan M DreyfussBioinformatics and Biostatistics Core, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
Ivan Carcamo-OriveDivision of Cardiovascular Medicine, Cardiovascular Institute and Diabetes Research Center, Stanford University School of Medicine, Stanford, California, USA.
Joshua W KnowlesDivision of Cardiovascular Medicine, Cardiovascular Institute and Diabetes Research Center, Stanford University School of Medicine, Stanford, California, USA.
Matthias MannDepartment of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany.
C Ronald KahnSection of Integrative Physiology and Metabolism, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA.
Joslin Diabetes Center · USCardiovascular Institute of the South · USMax Planck Institute of Biochemistry · DE

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI ROHIT N. KULKARNI · 1986 to 2026
$50.5M
Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Insulin Receptor Substrates and Insulin ActionR01DK033201 · NIDDK · JOSLIN DIABETES CENTER · PI KAHN, C RONALD · 1986 to 2016
$10.6M
The Insulin Receptor and Its Signaling MechanismsR01DK031036 · NIDDK · JOSLIN DIABETES CENTER · PI C RONALD KAHN · 1986 to 2026
$4.2M
Characterization of novel insulin resistance genes by gene editing, high-throughput phenotyping and in vivo studiesR01DK120565 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$3.2M
Alterations in Post-Receptor Insulin Signaling in Diabetes and Insulin ResistanceR01DK128429 · NIDDK · JOSLIN DIABETES CENTER · PI KAHN, C RONALD · 2021 to 2025
$2.9M
Interaction between genes, environment, the microbiome and metabolome in type 2 diabetes and metabolic syndromeR01DK121967 · NIDDK · JOSLIN DIABETES CENTER · PI KAHN, C RONALD · 2020 to 2024
$2.7M
Mechanisms of NAT2 Regulation of Insulin Resistance and Mitochondrial DysfunctionR01DK116750 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2019 to 2023
$2.4M
Beyond GWAS of insulin resistance: An integrated approach to translate genetic association to functionR01DK106236 · NIDDK · STANFORD UNIVERSITY · PI KNOWLES, JOSHUA WILEY · 2016 to 2020
$2.4M
Molecular Mechanisms of Insulin Resistance Associated LociR01DK107437 · NIDDK · STANFORD UNIVERSITY · PI QUERTERMOUS, THOMAS · 2016 to 2019
$2.2M
NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30 DK116074NIDDK NIH HHS R01 DK031036NIDDK NIH HHS R01 DK033201NIDDK NIH HHS R01 DK106236NIDDK NIH HHS R01 DK107437NIDDK NIH HHS R01 DK116750NIDDK NIH HHS R01 DK120565NIDDK NIH HHS R01 DK128429
6 · The paper itself

Abstract

Insulin resistance is present in one-quarter of the general population, predisposing these people to a wide range of diseases. Our aim was to identify cell-intrinsic determinants of insulin resistance in this population using induced pluripotent stem cell-derived (iPSC-derived) myoblasts (iMyos). We found that these cells exhibited a large network of altered protein phosphorylation in vitro. Integrating these data with data from type 2 diabetic iMyos revealed critical sites of conserved altered phosphorylation in IRS-1, AKT, mTOR, and TBC1D1 in addition to changes in protein phosphorylation involved in Rho/Rac signaling, chromatin organization, and RNA processing. There were also striking differences in the phosphoproteome in cells from men versus women. These sex-specific and insulin-resistance defects were linked to functional differences in downstream actions. Thus, there are cell-autonomous signaling alterations associated with insulin resistance within the general population and important differences between men and women, many of which also occur in diabetes, that contribute to differences in physiology and disease.

Indexed as

Insulin ResistanceSex CharacteristicsSignal TransductionDiabetes Mellitus, Type 2FemaleGTPase-Activating ProteinsHumansInsulin Receptor Substrate ProteinsMaleProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesGTPase-Activating ProteinsInsulin Receptor Substrate ProteinsIRS1 protein, humanMTOR protein, humanProto-Oncogene Proteins c-aktTBC1D1 protein, humanTOR Serine-Threonine KinasesInsulin signalingiPS cellsMetabolismStem cells

Identifiers

PMID34506305
PMCPMC8553553
OpenAlexW3196701843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.